Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$CUR - Neuralstem Phase I Confirmed Safety And Phase II Update

|Includes:Neuralstem, Inc. (CUR)

Presentation by Eva Feldman, PhD, MD, NSI-566/ALS Principal Investigator, Keystone Symposia, 4/9/14

http://bit.ly/R6rmoj

Slide #26 states:

Phase 1 Trial Confirmed Safety and
Phase 2 Trial is Underway

• Numbers are small but data suggest that transplantation in
subjects early in the disease course with no bulbar signs carries
less risk
• Phase 2: 11 subjects entered, all cervical injections
• 1-3 (NYSE:A): 5 bilateral inj; 200,000 cells/inj: 2 million cells
• 4-6 (NYSE:B): 10 inj/side: 200,000 cells/inj: 4 million cells
• 7-9 (NYSE:C): 10 inj/side: 300,000 cells/inj: 6 million cells
• 10-11 (NYSE:D): 10 inj/side: 400,000 cells/inj: 8 million cells
• Final cohort receives bilateral cervical (8 million) followed by
bilateral lumbar (8 million) injections for 16 million cells

No safety concerns; subjects doing well

Disclosure: I am long CUR.

Stocks: CUR